| Polymeric artificial tear system -> Monitor Keywords |
|
|
 
Polymeric artificial tear systemPolymeric artificial tear system description/claimsThe Patent Description & Claims data below is from USPTO Patent Application 20090270345, Polymeric artificial tear system. Brief Patent Description - Full Patent Description - Patent Application Claims
This application claims priority under 35 U.S.C. §119 to U.S. Provisional Patent Application No. 61/048,175, filed Apr. 26, 2008, the entire contents of which are incorporated herein by reference. The present invention relates to artificial tear formulations and formulations for ophthalmic drug delivery, and more specifically to galactomannan-borate polymer systems comprising a cis-diol. Many ophthalmic formulations comprise compounds that provide lubricity and other desirable properties. When these formulations are instilled in the eye, the properties of such compounds can prevent undesirable problems such as bioadhesion and the formation of friction-induced tissue damage, as well as encourage the natural healing and restoration of previously damaged tissues. Many marketed artificial tear solution products contain polymers that display thixotropic and viscoelastic properties. Some of these polymers include hydroxypropylmethylcellulose, galactomannans such as guar and hydroxypropyl guar, carboxymethylcellulose, hyaluronic acid, and sodium alginate. The shear thinning and viscoelastic profiles of polymers play important roles when mixed with the tear film. The retention profile, lubrication and mucomimetic properties of polymers in artificial tear solution products may play an important role by to helping stabilize the tear film and providing improved comfort to patients with dry eye disease. For example, the product Systane® (Alcon, Inc.) containing hydroxypropyl guar and the active ingredients polyethylene glycol 400 and propylene glycol has been reported by Paugh, et al. (2008) to be more effective at eliminating eye discomfort than similar viscosity enhancing polymers such as carboxymethyl cellulose. The bulk rheology of polymers used in artificial tear solutions is often characterized by steady state shear (shear thinning) and dynamic oscillation tests (viscoelasticity). Although these tests are valuable, these bulk rheology experiments may not fully characterize the interfacial properties of such polymers. An understanding of the polymers\' interfacial properties is critical, as these properties may play important roles in the interactions with tear film components at both the cornea/tear film interface and tear film/air interface. Another rheology test that can aid in understanding the dynamic and interfacial properties of polymers used in artificial tears is the oscillation drop experiment, described herein. Ophthalmic formulations have been previously described that utilize galactomannan-borate gelling systems. U.S. Pat. No. 6,403,609 to Asgharian, entitled “Ophthalmic compositions containing galactomannan polymers and borate,” describes such systems and is herein incorporated by reference in its entirety. The cross-linking of galactomannan and borate is responsible for the gel-forming behavior of the described formulations. The present invention generally relates to ophthalmic formulations comprising galactomannan, including galactomannans such as guar or hydroxypropyl guar. The formulations of the present invention also comprise a borate source such as boric acid. A cis-diol, such as sorbitol or propylene glycol, is present in the formulations and interferes with the cross-linking of the galactomannan and borate. The cis-diol is selected based on its diffusion characteristics relative to the galactomannan. Typically, the ophthalmic formulations of the present invention comprise a cis-diol that is a relatively small molecule such as sorbitol that diffuses more rapidly than the galactomannan in the ocular tear film. Upon installation in the eye, the concentration of the cis-diol decreases at a different rate than the galactomannan, allowing the galactomannan and borate to cross-link a form a structured polymer network in situ. Thus, the gelling behavior and rheological characteristics of the formulations after installation into the eye are controlled via selection of the cis-diol. The formulations of the present invention are substantially free of divalent cations such as magnesium, zinc and calcium that can strengthen cross-linking of the galactomannan and borate. Once a formulation is instilled in the eye, divalent cations present in the tear film enhance formation of a structured galactomannan-borate polymer network. The formulations of the present invention are also useful as drug delivery vehicles for ophthalmic therapeutics. Upon installation of a formulation in the eye, a galactomannan-borate polymer network is formed; this network is able to hold various therapeutic agents on the eye, including demulcents. The foregoing brief summary broadly describes the features and technical advantages of certain embodiments of the present invention. Additional features and technical advantages will be described in the detailed description of the invention that follows. A more complete understanding of the present invention and the advantages thereof may be acquired by referring to the following description, taken in conjunction with the figures of the accompanying drawing in which like reference numbers indicate like features and wherein: Continue reading about Polymeric artificial tear system... Full patent description for Polymeric artificial tear system Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Polymeric artificial tear system patent application. Patent Applications in related categories: 20090281057 - Botanically derived composition and a process thereof - The present invention relates to a novel botanical compound as provided in structural formula I optionally along with excipients for improving body composition and the factors related to the pre-diabetic and diabetic conditions. It also relates to a process of manufacture of the novel botanical compound for improving body composition ... 20090281057 - Botanically derived composition and a process thereof - The present invention relates to a novel botanical compound as provided in structural formula I optionally along with excipients for improving body composition and the factors related to the pre-diabetic and diabetic conditions. It also relates to a process of manufacture of the novel botanical compound for improving body composition ... 20090281056 - Cationized hyaluronic acid - The present invention provides a cationic polymer which is much closer to the component of a human body, and capable of forming a polyion complex together with an anionic material such as hyaluronic acid. The cationized hyaluronic acid of the present invention is a hyaluronic acid wherein at least one ... 20090281056 - Cationized hyaluronic acid - The present invention provides a cationic polymer which is much closer to the component of a human body, and capable of forming a polyion complex together with an anionic material such as hyaluronic acid. The cationized hyaluronic acid of the present invention is a hyaluronic acid wherein at least one ... ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Polymeric artificial tear system or other areas of interest. ### Previous Patent Application: Immunoregulatory agent Next Patent Application: Polysaccharide extract of lentinus and pharmaceutical, cosmetic or nutraceutical compositions comprising such an extract Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the Polymeric artificial tear system patent info. IP-related news and info Results in 2.25584 seconds Other interesting Feshpatents.com categories: Accenture , Agouron Pharmaceuticals , Amgen , AT&T , Bausch & Lomb , Callaway Golf paws |
 * Protect your Inventions * US Patent Office filing 
PATENT INFO |
|
